Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- SYBX
- Price
- 1.02
- Stock movement down
- -0.04 (-3.30%)
- Company name
- Synlogic Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 11.99M
- Ent value
- 246.50K
- Price/Sales
- 4.32
- Price/Book
- 0.91
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -21.95%
- 1 year return
- -43.68%
- 3 year return
- -69.16%
- 5 year return
- -47.60%
- 10 year return
- -
Last updated: 2025-04-12
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
SYBX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 4.32 |
| Price to Book | 0.91 |
| EV to Sales | 0.09 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 11.70M |
| EPS (TTM) | -3.62 |
| FCF per share (TTM) | -3.06 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 2.78M |
| Gross profit (TTM) | 211.00K |
| Operating income (TTM) | -21.53M |
| Net income (TTM) | -44.20M |
| EPS (TTM) | -3.62 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | 7.60% |
| Operating margin (TTM) | -775.15% |
| Profit margin (TTM) | -1591.75% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 19.39M |
| Net receivables | 0.00 |
| Total current assets | 20.70M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 20.75M |
| Accounts payable | 178.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 7.65M |
| Total liabilities | 7.65M |
| Shareholder's equity | 13.11M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -36.62M |
| Capital expenditures (TTM) | 804.00K |
| Free cash flow (TTM) | -37.42M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -337.22% |
| Return on Assets | -212.98% |
| Return on Invested Capital | -337.22% |
| Cash Return on Invested Capital | -285.49% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.03 |
| Daily high | 1.05 |
| Daily low | 0.95 |
| Daily Volume | 2K |
| All-time high | 990.15 |
| 1y analyst estimate | 1.00 |
| Beta | 0.84 |
| EPS (TTM) | -3.62 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 12 May 2025 |
Downside potential
Loading...
Downside potential data
| SYBX | S&P500 | |
| Current price drop from All-time high | -99.90% | -12.89% |
| Highest price drop | -99.90% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -88.14% | -11.07% |
| Avg time to new high | 596 days | 12 days |
| Max time to new high | 2330 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
11.99M
Marketcap category
Small-cap
Description
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.
Employees
6
Website
Investor relations
-
SEC filings
CEO
Aoife M. Brennan
Country
USA
City
Cambridge
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page